An official website of the United States government
Home
SEER Inquiry System - Report
Produced: 12/27/2024 9:01 PM
Question 20210077
Inquiry Details
References:
2021 SEER Manual, 222-231. Neoadjuvant Therapy data items
Question:
First Course Therapy/Neoadjuvant Treatment: How are Neoadjuvant Therapy--Clinical Response and Neoadjuvant Therapy--Treatment Effect coded when the neoadjuvant therapy was not completed? Does the entire course of neoadjuvant therapy need to be completed before we can code these fields? See Discussion.
Discussion:
Example: The neoadjuvant therapy was started, the patient progressed, the treatment plan was altered, and a new course of systemic therapy was started; surgery was cancelled.
01/25/21 Bile duct brushing: Malignant cells present, adenocarcinoma
01/26/21 Surgical oncology consult: Currently unresectable; recommend neoadjuvant chemo
02/22/21-3/29/21 Neoadjuvant Gemzar & Abraxane, two cycles, discontinued due to disease progression
04/17/21 Surgical oncology re-eval: CT positive for disease progression, need to change Rx
04/26/21 Second change of treatment due to progression: Irinotecan, Oxaliplatin, and 5FU
07/16/21 Surgical oncology re-eval: Unresectable, advise 4-6 months of chemo followed by radiation
Answer:
Assign code 3 (Progressive disease (PD)(per managing/treating physician statement) for Neoadjuvant Treatment--Clinical Response and code 7 (Neoadjuvant therapy completed and planned surgical resection not performed) for Neoadjuvant Treatment--Treatment Effect. These are the best choices under the circumstances. Use text fields to record the details.
